China's new stimulus package: finally, the turning point?

Measures announced last week are the most comprehensive stimulus policy actions undertaken in recent years in terms of scale and urgency.

Whilst markets have all but lost patience when it comes to the China recovery, the measures announced by China’s Central Bank last week are the most comprehensive stimulus policy actions undertaken in recent years in terms of scale and urgency and are likely to provide meaningful stock market support.

The measures are a combination of monetary and fiscal support that will include funding from ultra long term and special sovereign bonds.

This was confirmed at an out-of-cycle economic Politburo meeting, usually reserved for exceptional circumstances, the last of which was held in March 2020 at the peak of Covid-19 concerns.

The direction of such fiscal spending is yet to be detailed but the strongest indication are that it is to be spent on initiatives to drive consumption, along with a capital injection into the banking system of around RMB1 trillion.

Managed Fund
Antipodes Global Fund – Long
Global Shares
ETF
Antipodes Global Shares (Quoted Managed Fund) (AGX1)
Global Shares

Key stimulus policy measures:

  • A 30-basis point cut in the 1-year medium-term lending facility rate (from 2.60% to 2.30%).
  • A 20-basis point cut in the 7-day reverse repo rate (from 1.90% to 1.70%).
  • Reserve requirement ratio (RRR) cut by 50bps which frees up ~$142bn USD of liquidity.
  • Lower mortgage rates for existing loans
  • Down payment ratio for second homes cut to 15% from 25%.
  • PBOC directive allowing financial institutions to borrow for stock investments - 500bn RMB facility.
  • PBOC providing subsidised funds to be used for share buybacks and purchases by controlling shareholders - 300bn RMB facility
  • Funding for such initiatives can grow if there is evidence they are working.

Key areas in which these measures will likely have meaningful impacts

The property and consumer sector could benefit from a reduction in mortgage rates and down payment ratios could increase housing market activity, stabilise pricing and general consumption. In financial markets, measures aimed at providing stock market support, in addition to recent reform (including the promotion of share buybacks) could help stabilise markets and attract value orientated investors. And finally, corporate liquidity is another area to watch. By increasing liquidity into the system, the PBOC wants to encourage further lending and flows into risk/growth assets.

While the Chinese economy is not yet out of the woods, the range of outcomes are converging towards larger stimulus and a return to growth/inflation or at least addressing the issue of deflation in the next year. Such an improvement in the economy is not priced in equities that remain compelling on mid cycle earnings assumptions.

Based on the next 12 months consensus earnings, MSCI China remains at the bottom of its historical valuation range at 10.2x next 12 months PE.

Investment opportunities 

Against this backdrop, we continue to see three broad buckets of opportunity for investors:

  1. Attractively priced cyclicals that have consumer and property exposure. Opportunities include Alibaba and KE Holdings (the largest property portal in China, with a disproportionate share of secondary transactions, where sales are inflecting).
  2. Defensive businesses such as China Mengniu Dairy and Tsingtao Brewery (second largest beer company operating in a consolidated market).
  3. Structural growth opportunities around advertising and AI adoption, localisation, and decarbonisation. Nari Technology is a stock to watch with the company’s modern grid equipment and technology solutions in high demand as renewables and complementary build-out in ultra-high voltage infrastructure grows).

Build exposure to China and Emerging Markets with Antipodes

Antipodes Partners is an award-winning investment manager with over $10 billion in AUM and a dedicated emerging markets investment team managing over $2 billion invested across the asset class. 

Keep up to date with Antipodes' insights on LinkedIn. Or subscribe to receive news and insights via email on the Antipodes website

........
All content in respect of the Antipodes Global Shares (Quoted Managed Fund) (ARSN 625 560 269), the Antipodes Global Fund – Long (ARSN 118 075 764), the Antipodes Global Fund (ARSN 087 719 515), and the Antipodes Asia Fund (ARSN 096 451 393) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Funds and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice. The information provided is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Funds, you should consider the current Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the Funds and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser. The Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the relevant Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund. Links to these documents can be found at antipodes.com. For historic TMD’s please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Funds. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this content. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.

1 topic

1 stock mentioned

John Stavliotis
Sector Head
Antipodes

John is a senior member of Antipdoes’ emerging markets investment team. Prior to joining Antipodes in 2018, John was a sell-side Analyst with Morgan Stanley for four years and earlier in his career held research analyst roles with Bligh Capital...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment